CTC and ctDNA Testing Liquid Biopsy—CSF

biocept.com

A New Opportunity for Breast and Lung Cancer Patients with CNS Involvement

Biomarker results from cerebral spinal fluid (CSF)

Biocept.com2

Biocept’s test can detect CTCs and ctDNA in cerebral spinal fluid (CSF) to perform biomarker testing for identification of targeted therapies for breast and lung cancer patients with CNS involvement

From a lumbar puncture procedure, cerebral spinal fluid (CSF) is collected into CEE-Sure™ collection tube.

Biocept patented technology captures circulating tumor cells (CTCs) and isolates circulating tumor DNA (ctDNA).

CTC Capture ctDNA Isolation

��� ��� ��� ��� ��� ��� ��� ��� ��� �

� � � � �� �� �� �� �� �� �� �� �� �� �� �� �� �� �� ��������������

G-Black C-Blue T-Red A-Green

DNA Isolation

Patented Switch-Blocker Technology

qPCR Mutation Detection

Sanger Sequencing

Copy Number Variations

Antibody Cocktail CTC Isolation

ICC for Proteins

FISH for Rearrangements

Detection, Enumeration and Biomarker Analysis all in the channel

CTC

Patented Microfluidic Channel

Biocept.com3

Biocept’s test can detect CTCs and ctDNA in cerebral spinal fluid (CSF) to perform biomarker testing for identification of targeted therapies for breast and lung cancer patients with CNS involvement

Target Selector™ biomarker testing is performed on captured CTCs and isolated ctDNA.

Targeted therapies potentially identified for breast and lung patients with CNS involvement.

Actionable NCCN Biomarkers for breast and lung cancer patients with CNS involvement

Targeted Therapy Associated with Biomarker

ALK Alecensa®, Alunbrig®, Xalkori®, Zykadia®

BRAF Cotellic®, Mekinist®, Tafinlar®, Zelboraf®

EGFR Gilotrif®, Iressa®, Tagrisso®, Tarceva®

HER2 Herceptin®, Perjeta®, Tykerb®, Kadcyla®

NTRK1 Rozlytrek™, Vitrakvi®

PD-L1 Keytruda®, Opdivo®, Tecentriq®

ROS1 Xalkori®

Biocept test menu includes, but is not limited to, NCCN biomarkers for patients with breast and lung cancer with CNS involvement. For complete biomarker list, visit Biocept.com/biomarkers

Biocept.com4

Biocept Target Selector™ outperforms cytology in CTC detection

• Biocept detected CTCs in CSF of confirmed patients with leptomeningeal disease 32% more often than cytology.1

• In matched CSF specimens of patients confirmed with leptomeningeal disease, Biocept detected CTCs 13% more often than cytology.1

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

CTC Detection Rate

Biocept80%(n=49) Cytology

48%(n=31)

55%

60%

65%

70%

75%

80%

CTC Detection Rate

Biocept75% Cytology

62%

CTC Detection Rates in Patients with Confirmed Leptomeningeal Disease1

CTC Detection Rates in Matched Patient Samples Before Treatment with Confirmed Leptomeningeal Disease (n=24)1

Biocept.com5

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Clinical Accuracy/Concordance

Clinical Specificity Clinical Sensitivity Positive PredictiveValue (PPV)

Negative PredictiveValue (NPV)

CTC ctDNA

Biocept Target Selector™ provides actionable biomarker testing for potential targeted therapy options

85%

15%

CTC DetectedCTC Not Detected

35% gene amplification in CSF of patients with confirmed leptomeningeal disease

95% activating mutation detection in ctDNA of patients' CSF with confirmed leptomeningeal disease and treated with tyrosine kinase inhibitors (TKI)

References1 Preliminary raw data from Biocept’s internal research. Manuscript available upon request.2 Singh, V. et al., Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM, Poster presented at 2018 WCLC Meeting.

Actionable Biomarker Testing Results2

n=20 (patients with confirmed leptomeningeal disease)

Robust Test Performance1

Biocept.com6

Biocept provides a user-friendly, informative test report

Relevant images

Quantitation of CTC capture (overall and subgroups)

Clear, quick to understand results for CTC capture, FISH, and ICC

Biocept.com7

Comprehensive biomarker menu aligned with NCCN and actionable treatment options

A

A

CTC and ctDNA Testing Liquid Biopsy—CSF

Liquid Biopsy—CSFfor CTC and ctDNA Detection & Biomarker Results

© 2020 Biocept, Inc. All rights reserved. Target Selector is a trademark of Biocept, Inc. MKTG-0086.01

Customer Service 888-332-7729 • FAX 877-300-1761Biocept, Inc.5810 Nancy Ridge Drive, San Diego, CA 92121

www.biocept.com

Most health plans, including Medicare, cover our testing if certain criteria are met. Biocept will bill insurances on behalf of the patient; however, as with most coverage, a patient may have a balance (co-pay, deductible, or co-insurance) based upon the individual benefit design of the patient’s policy. For any amounts owed by a patient, Biocept has a Financial Assistance Program (see Billing Policy online) based on the patient’s financial situation. We are committed to excellence and are here to assist with any questions or concerns you may have.

Insurance Coverage